Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
All content for The Swiss Connection is the property of SWI swissinfo.ch and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
Switzerland and Silicon Valley: EP4 Pamela Munster ‘From cancer doctor to cancer patient and back again’
The Swiss Connection
20 minutes
1 year ago
Switzerland and Silicon Valley: EP4 Pamela Munster ‘From cancer doctor to cancer patient and back again’
Send us a text Pamela Munster, a world-renowned oncologist, has been working in San Francisco for 15 years. In this episode, she recounts her battle against breast cancer. You can find more written and video content about this story on SWI swissinfo.ch: in English in French (original) in German Journalist: Marc-André Miserez Host: Jo Fahy Audio editor/Video: Michele Andina Distribution and Marketing: Xin Zhang SWI swissinfo.ch is a ...
The Swiss Connection
Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
